
Community-based Case Studies of Vaccine Hesitancy and the COVID-19 Response in 1
South Africa; The VaxScenes Study 2

Charles Shey Wiysonge ^{1¶}, Nancy Coulson ^{2,3¶}, Nirvana Pillay ^{2,4¶}, Sara Cooper ¹, 3
Candice Groenewald ^{5,6}, Zaynab Essack ^{5,7}, Saahier Parker ⁸, Gregory Houston ⁹, Jane 4
Simmonds ¹⁰, Anelisa Jaca ¹, Muyunda Mutemwa ¹¹, Patrick DMC Katoto¹ and Heidi 5
van Rooyen ^{8,12}. 6

¹ Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa 7

² The Sarraounia Public Health Trust, Johannesburg, South Africa 8

³ Wits Mining Institute, University of the Witwatersrand, Johannesburg, South Africa 9

⁴ School of Public Health, University of the Witwatersrand, Johannesburg, South Africa 10

⁵ Centre for Community Based Research, Human Sciences Research Council, Durban, South
Africa; 11
12

⁶ Department of Psychology, Rhodes University, Makhanda, South Africa 13

⁷ South African Research Ethics Training Initiative, University of KwaZulu-Natal,
Pietermaritzburg, South Africa 14
15

⁸ The Impact Centre, Human Sciences Research Council, Cape Town, South Africa; 16

⁹ Developmental, Capable and Ethical State research division, Human Sciences Research
Council, Cape Town, South Africa; 17
18

¹⁰ Office of the President and CEO, South African Medical Research Council, Cape Town,
South Africa; 19
20

¹¹ Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research
Council, Cape Town, South Africa; 21
22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹² SAMRC-Wits Developmental Pathways for Health Research Unit, University of the 23

Witwatersrand, Johannesburg, South Africa 24

25

* Correspondence: Charles.Wiysonge@mrc.ac.za (C.S.W.) and nirvana@sarraounia.org 26

(N.P.). 27

[¶]CS Wiysonge, N Coulson, and N Pillay contributed equally to this manuscript and share 28

joint first authorship. 29

30

Funding: The APC is funded by the South African Medical Research Council and the study 31

is funded by the Human Sciences Research Council, South Africa. 32

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in 33

the design of the study, in the writing of the manuscript, or in the decision to publish the 34

results. 35

Data Availability Statement: Not applicable. 36

38

39

Abstract: 40

Background 41

South Africa has reported more than half of all COVID-19 cases and deaths in Africa. The 42
South African government has launched a large COVID-19 immunization campaign with the 43
goal of reaching more than 40 million individuals. Nonetheless, certain international, largely 44
internet-based surveys have shown a significant proportion of vaccine hesitancy in South 45
Africa. This study aims to determine and co-create with local stakeholders a comprehensive 46
understanding of vaccine hesitancy and opportunities to support the promotion of other 47
COVID-19 health-promoting behaviours at community level. 48

Methods and design 49

A mixed-methods, multiple case-study design; informed by the socio-ecological model of 50
behaviour change. Four socio-economically diverse communities across South Africa will be 51
selected and data collection will take place concurrently through three iterative phases. Phase 52
1 will provide insights into community experiences of COVID-19 (response) through desktop 53
mapping exercises, observations, in-depth interviews, and focus group discussions (FGDs) 54
designed as expression sessions with local stakeholders. Phase 2 will explore the extent and 55
drivers of community acceptance of COVID-19 vaccines. This phase will comprise a 56
quantitative survey based on WHO's Behavioural and Social Drivers of Vaccination tool as 57
well as further FGDs with community members. Phase 3 will involve cross-case study 58
syntheses and presentation of findings to national role-players. 59

Discussion 60

This study will provide ground up, locally responsive, and timeous evidence on the factors 61
influencing COVID-19 health-seeking behaviours to inform ongoing management and 62

mitigation of COVID-19 in South Africa. It will also provide insights into the applicability of 63
a novel vaccine hesitancy model in Africa. 64

Keywords: South Africa; COVID-19 response; vaccine hesitancy; case studies; behavioural 65
and social drivers of vaccination; non-pharmaceutical interventions 66

1. Introduction 67

South Africa first went into national lockdown on 26 March 2020 in response to the coronavirus 69
disease 2019 (COVID-19) pandemic and has since aligned with international guidance led by 70
the World Health Organization (WHO) on how to manage the unprecedented pandemic in the 71
face of emergent scientific evidence [1, 2]. Lockdown regulations implemented in varying 72
degrees by the South African government responded to the waves of COVID-19 amidst 73
increasing uncertainty and social and structural damage to South Africa [3]. During the first 74
quarter of 2021, the country experienced serious levels of COVID-19 infections as the second 75
wave of the COVID-19 epidemic unfolded across the country [4]. Internationally and locally, 76
new variants of COVID-19 were found to be more infectious and the surge in COVID-19 cases 77
at the beginning of 2021 was more serious than the infection levels experienced at the start of 78
the pandemic in 2020 [5]. 79

The scientific pursuit of biomedical interventions to manage COVID-19 saw the proliferation 81
of studies on drug and vaccine efficacy during 2020 [6]. Over the year, the need to manage and 82
translate the changing landscape of COVID-19 evidence as it emerged was ever-present. This 83
complicated the implementation and maintenance of behavioural interventions regarding non- 84
pharmaceutical interventions (NPIs), but also emphasised the need for NPIs given we had 85
nothing else at the time. In early 2021, NPIs were the only available and accessible methods to 86

reduce and prevent the spread of COVID-19 in the country [1, 2]. At the same time, the safety 87
and efficacy of a number of COVID-19 vaccines had been established and the manufacture, 88
procurement, and rollout of these vaccines was a global priority [7]. Contrary to high-income 89
countries, at the beginning of 2021, limited numbers of vaccine doses had been procured for 90
South Africa and ongoing procurement and rollout was uncertain [8]. However, vaccinating 91
the South African population at scale with efficiency was a top government priority. COVID- 92
19 vaccine uptake will involve behaviour change at a large scale as the government aims for a 93
vaccination coverage of at least 67% of the South African population in order to control 94
COVID-19 infections in the country [9]. 95

Vaccine hesitancy is one of the main challenges to be addressed for the vaccine programme to 97
work in South Africa [10]. Vaccine hesitancy, according to WHO's global working group on 98
“Measuring Behavioural and Social Drivers of Vaccination” (BeSD) is a “motivational state of 99
being conflicted about, or opposed to, getting vaccinated” which includes intentions [11]. 100
Limited evidence available in early 2021 showed wide variation in COVID-19 vaccine 101
hesitancy from 18% to 48% across various time points and geographical locations in South 102
Africa [12, 13]. Many elements could have contributed to the vaccine hesitancy. For example, 103
previous experiences that communities have of the delivery of healthcare services could 104
influence both vaccine intentions and uptake [14]. Contextual factors that shape the enabling 105
environment for vaccine uptake within a middle-income country like South Africa might be 106
expected to play a bigger role in levels of vaccine hesitancy when compared with the results 107
found in other studies which are largely conducted in high-income countries [15, 16]. For 108
example, the availability and cost of transport is regularly a barrier to access to healthcare 109
services in resource constrained communities [17, 18]. In addition, the dominance of social 110
media has been shown in a global study to directly impact on vaccine uptake [19]. Even before 111

the COVID-19 pandemic, South Africans were increasingly finding themselves in echo chambers of fake information about vaccination on social media and the internet [20-26].

Ensuring optimal uptake of COVID-19 vaccines in South Africa would thus involve multiple factors including knowledge, creating an enabling environment, addressing social influences, and personal motivation [18, 27, 28]. The preceding sections highlight the need for a ground up, contextually informed approach, that recognises the lived experience and understanding of individuals and places them in the social world in which they live and work. That was the rationale for the proposed VaxScenes Study, which aims to determine and co-create with local stakeholders in four diverse South African communities, a comprehensive understanding of vaccine hesitancy and opportunities to support the promotion of COVID-19 health seeking behaviours.

2. Materials and Methods

The specific objectives are to:

1. Create a community-based COVID-19 relevant geographic information system (GIS) picture that can be used for local planning in the COVID-19 response, including for vaccination and NPIs to curb the spread of COVID-19.
2. Document stories of the lives of community members affected by COVID-19 sickness, death, and economic loss in four communities.
3. Use the socio-ecological model to provide a community level assessment of the barriers and enabling factors at various levels (personal, interpersonal, community, and social/political) to vaccine acceptance and for ongoing adherence to behavioural measures.

4. Pilot the BeSD survey tool to provide guidance on its application in South Africa and to baseline vaccine hesitancy at the local level. 135
136
5. Co-create with community-level stakeholders, context sensitive strategies to address vaccine hesitancy and COVID-19 health seeking behaviours to guide both local and national responses. 137
138
139

140
141 Four community-based case studies will be undertaken using the socio-ecological model
142 [29]. The research methods to be applied in the case studies are described in further detail in
143 the following sections. Each component of data collection will be complemented by a process
144 of engagement with stakeholders at the community level, described as action research [30].
145 These stakeholders will be identified during community-level mapping, and will include local
146 community leadership and service providers, such as health facility managers and school
147 principals. These and other key informants will be interviewed and then invited to participate
148 in workshops to contribute to the interpretation of findings and to co-create community-level
149 strategies to address vaccine hesitancy and to strengthen the COVID-19 response as findings
150 become available.

2.1. Conceptual framework 151

152 We propose using the socio-ecological model [29] for behaviour change as a framework
153 to understand how to increase COVID-19 vaccine uptake by looking at barriers and enabling
154 factors at various levels, ranging from the individual to the interpersonal (the influence of
155 family, peers) to the community, and to the wider context (policy, infrastructure, resources).
156 Health messaging and correct information, although important, is often not enough for people
157 to implement sustainable behaviour change. The socio-ecological model acknowledges that for
158 any behaviour change to be maintained and sustained, it needs to happen at many different

levels. Information about the COVID-19 vaccine in isolation to other interventions will not be 159
sufficient to get the uptake required for herd immunity; information and strategies that address 160
vaccine hesitancy and that motivate people to access COVID-19 vaccines are also needed. It is 161
critical to behaviour change in a community that all four of the levels - personal, interpersonal, 162
community, and social/political - be capacitated for a change in behaviour to occur in many 163
people and then be maintained and sustained. Box 1 illustrates how the different levels of the 164
socio-ecological model can be applied to address vaccine hesitancy. In practice, we will 165
contextualise tools recently developed by the BeSD working group and use them in this study. 166
The BeSD framework consists of four domains that could potentially shape vaccine intentions 167
and uptake, namely, what people think and feel about vaccines; social processes that drive or 168
inhibit vaccination; individual motivations (or hesitancy) to seek vaccination; and practical 169
factors that shape the experience of seeking and receiving vaccination [14]. 170

Box 1: Applying the socio-ecological model to address vaccine hesitancy

Individual (Self): understand the information about the vaccine (know that it is available and it is recommended that you get it), be motivated to get it, and be able to get access

Interpersonal: getting the vaccine needs support from partners, family members, and peers, or at least encouragement for this behaviour

Community: getting the vaccine needs to become a social norm and the socially accepted and expected thing to do. You need to be able to access the vaccine easily and safely at a local primary healthcare facility, doctor or workplace. Religious organisations, community organisations, local leaders, traditional leaders, traditional healers, and other influencers (social and political) need to be supportive of vaccine uptake

Environment: At a public policy level, the availability of the vaccine needs to be secured and the vaccine needs to be available. Resources need to be available to place vaccination centres within easy reach of the community.

The BeSD tools include qualitative tools (in form of guides for in-depth interviews with 172
stakeholders), quantitative tools (that is, questionnaires for population surveys), and a 173
guidebook to support implementation of the tools. The tools focus on childhood vaccination 174

and COVID-19 vaccination for health workers and for adults [14]. We will adapt the BeSD 175
COVID-19 vaccination tools for adults to our local context [31]. 176

Figure 1. The Behavioural and Social Drivers of Vaccination
Framework. Source: The BeSD Working Group [11, 14].

2.2. Study design 181

This research is designed as multiple case studies of four sites. Case study research is empirical 182
research that explores a contemporary phenomenon within its real-world context [32]. Case 183
studies are especially useful when the boundaries and interface between the “phenomenon” (or 184
“the case”) and the “context” are not so clear. Case studies usually rely on multiple sources of 185
data. In our study, the “phenomenon” is the introduction of COVID-19 vaccination into the four 186
selected communities in South Africa with their different contextual factors, histories, and 187
experience of COVID-19. Case studies are dominated by ‘how and why’ research questions. By 188
adopting an approach that relies on more than one data collection method, it is possible through 189
a case study to describe, explore, and explain the “how and why” of possible vaccine hesitancy 190
without presuming at the outset to know the contextual and other factors that are shaping local 191
behaviour. The research methods will be carefully replicated at each site; the underlying goal 192
being either that the research will provide the replication of results across sites or that the case 193
studies will provide theory that can predict either similar or contrasting findings across different 194
communities [32]. In either case, multiple case studies will provide evidence that will be 195
helpful to the activities of the South African Government in addressing vaccine hesitancy. 196

2.3. Study settings 197

Table 1 shows the site selection of the four case studies. Convenience and purposive sampling were used in the selection of sites. Convenience sampling ensured that some sites which are well known to the study team with established research and community networks to facilitate speedy data collection can be used. Purposive sampling will allow the team to include a mix of sites from different South African provinces badly affected by COVID-19 and to include communities that reflect formal and informal urban contexts as well as peri-urban and rural environments. Study sites were selected in KwaZulu Natal, Gauteng, and Western Cape provinces, which were the three provinces with highest numbers of COVID-19 cases in South Africa in early 2021 [33]. In KwaZulu Natal Province we selected an urban community (Wentworth) and a semi-rural one (Sweetwaters). In Gauteng Province we selected an urban informal community known as Alexandra. Finally, in the Western Cape Province, an urban middle-class community was selected. The selected sites have markedly different populations as shown in Table 1.

Table 1. Characteristics of the four case study sites.

Site	Province	Administrative description	Type	Population	Provincial COVID-19 data*
Alexandra	Gauteng	Ward 76, RegionE City of Johannesburg	Urban, informal	798,014	386,770 cases; 10,195 deaths
Rylands	Western Cape	Ward 46, Athlone, City of Cape Town	Urban	32,199	268,507 cases; 10,195 deaths
Sweetwaters	KwaZulu-Natal	Vulundlela, Umgungundlovu District Municipality	Semi-rural	35,000	311,877 cases;
Wentworth	KwaZulu-Natal	Ward 66, eThekweni Municipality	Urban	145,949	8,443 deaths

The source of the provincial COVID-19 data is the South African National Department of Health, as reported on 29 January 2021 [33].

2.4. Study phases

At each case study site, teams will use a mixed methods approach to data collection with quantitative and qualitative elements to address all research objectives. Figure 1 illustrates the overall approach to the study that is to be replicated in each of the case study sites. At each site data collection and the dissemination of findings will be organised into three distinctive phases.

Figure 2. The three phases of data collection and dissemination for the VaxScenes Study. (BeSD, behavioural and social drivers of vaccination; KIIs, key informant interviews; FGDs, focus group discussions; GIS, geographic information system; MAC, ministerial advisory committees)

Phase 1 will provide a preliminary snapshot of the community experiences of COVID-19 and the responses to it. This will be achieved using GIS maps to visualise the spatial arrangements for infrastructure, housing, employment, and public and private services, as well as population centres and COVID-19 statistics. Thereafter key informant interviews (KIIs) with community stakeholders and focus group discussions (FGDs) designed as expression sessions will provide a narrative about the COVID-19 experience in the local community. The local map and narrative will be shared with key informants at a workshop where the findings will provide the basis for the selection of population groups for a deeper investigation of vaccine hesitancy in phase 2.

237

In **Phase 2**, the case study research design will throw a spotlight on community acceptance of COVID-19 vaccines. A quantitative survey and further FGDs will be conducted with groups in the community. The findings of the survey and focus group discussions will be shared with the key informants at a second workshop and this will form the basis for stakeholders co-creating strategies to maximise vaccine acceptance within their ward.

238
239
240
241
242
243

Phase 3 will involve cross case study syntheses as appropriate, and the presentation of findings to national role-players including the National Department of Health (NDoH), the Ministerial Advisory Committee (MAC) on COVID-19 Vaccines, the MAC on COVID-19, and the Behaviour Change Communication MAC. In Phase 3 researchers will prepare an integrated report across all four case study sites. Academic papers will be prepared and complemented by a comprehensive literature review of vaccine hesitancy and behavioural interventions as specifically experienced in Africa and in other cases where local perspectives about vaccine acceptability are integrated into national vaccine programmes.

244
245
246
247
248
249
250
251
252

2.5. Study population

253

Table 2 summarises the study population for both the qualitative and quantitative components.

254

The study will only recruit people who are aged 18 years or older.

255

Table 2. Sampling method and size per research methodology type at four case sites.

256

257

Research methodology	Sampling method	Sample size per site	Sample size for all 4 sites
Phase 1 research activities			
Key informant interviews(KIIs)	Purposive and snowballing	15-20 KIIs with stakeholders	70-80 KIIs with stakeholders
Observation	Observation sites selected through mapping & KIIs	Visits to 6 meeting spaces in the community for observation	Visits to 24 meeting spaces in the community for observation
Focus group discussions (FGDs) – expression sessions	Purposive	3 expression sessions each with 6 participants who have been badly affected by COVID-19 either through sickness, death, or economic loss.	12 expression sessions with a total of 72 participants who have been badly affected by COVID-19 either through sickness, death, or economic loss.
Phase 2 research			

activities			
BeSD survey	Convenience sampling	300 respondents from a maximum of 3 priority target groups for vaccination	1200 respondents from priority target groups for vaccination
FGDs with semi-structured guides	Purposive	3 FGDs with between 6 to 8 participants with stakeholders who shape social norms	12 FGDs with between 72 and 96 individuals with stakeholders who shape social norms

258

2.5.1. Study population for qualitative component

259

During Phase 1 we will conduct 15-20 key informant interviews (KIIs) with stakeholders who are purposively selected. The proposed list of ward-based key informants includes but is not limited to local political and traditional leadership, clinic and health service leaders, school principals, faith-based leaders, business leaders, government officials, local taxi associations, local civic leaders, local trade union leadership, and private healthcare practitioners. It is expected that key informants at each site will include many of the individuals listed above, but also that at each site a unique list of key informants will emerge iteratively. During the interviewing of key stakeholders, researchers will enquire after the names of other potential key informants to ensure that influential leadership at the local level is not inadvertently overlooked during the mapping exercise. Snowball sampling would ensure that the research team identifies all significant individuals shaping the local COVID-19 response who may, for example, be outside of the immediate community such as provincial and/or national role-players.

260

261

262

263

264

265

266

267

268

269

270

271

272

Participants for both types of FGDs will be purposively identified. Three FGDs of each type 273
will be held at each site. During Phase 1 no more than six participants will be recruited into the 274
expression sessions. The sessions will be implemented in a group setting consisting of no more 275
than six participants. The small sample size here is deliberate, to allow for meaningful 276
engagement in the focus group discussions. Participants who have been badly affected by 277
COVID-19 either through sickness, death, or economic loss will be recruited into the 278
expression sessions. A social worker will be available at each site to ensure that any trauma 279
experienced during or after the sessions can be appropriately referred. In Phase 2, between six 280
and eight participants will be purposively recruited into the FGDs that are to be supported with 281
a semi-structured interview guide. Specifically, this group of respondents are those best placed 282
to influence social norms around vaccination in the community. The participants for these 283
FGDs will be identified at the end of Phase 1 and in discussion with community stakeholders. 284
This could include healthcare workers, faith-based leaders, community leadership, and other 285
community and social workers. 286

2.5.2. Study population for the quantitative component 287

The selection of survey respondents will be guided by priority populations in line with the 288
rollout phases and target groups for COVID-19 vaccination as determined by the NDoH. The 289
findings of Phase 1 research and consultation with local stakeholders will also determine the 290
final selection of the survey respondents. It is expected that it may include priority groups at 291
risk of COVID-19 (the elderly), essential service workers identified in each study site (for 292
example, teachers, taxi drivers, and people working in institutional care facilities) and other 293
adult men and women in the selected communities. The participants should also be resident or 294
working in the community where the survey is to be conducted. The study will use non- 295
probability convenience sampling because it is a cost- and time- effective method. It is 296
proposed to collect 300 completed survey questionnaires at each site. Non-probability 297

sampling can account for smaller samples such as 300 per site. A sample comprising at least 298
300 participants per site allows for the detection of small correlations ($r=0.2$) with at least 95% 299
power [34]. 300

2.6. Data collection 301

Three discrete but interlinking components of data collection will be undertaken for each 302
case study site. These are: desk review of demographic and epidemiological profiles and 303
available GIS mapping and literature; qualitative data collection methods; and quantitative data 304
collection using a questionnaire. 305

2.6.1. Desk based methods 306

A desktop mapping exercise using existing GIS and COVID-19 related document collection 307
will complement qualitative and quantitative data collection at each site. The desk review will 308
aim to create a comprehensive picture of each community. This will include a demographic 309
and epidemiological profile, and mapping of the local community using general spatial 310
planning data commonly stored on GIS and the collection of documents that describe the 311
COVID-19 response in the community. A COVID-19 relevant picture of each community will 312
be created, using GIS to support this, and will include: COVID-19 epidemiological profile, 313
population (numbers, priority and at-risk groups, and population centres), services and local 314
infrastructure (schools, clinics, transport routes) taxis, buses, private, civil society (faith-based, 315
women's groups, non-governmental organisations, government offices), relevant government 316
departments, police, private sector (large employers and trade union representatives, private 317
health care, COVID-19 response (who has done what where and the size of the spend). The 318
desk-based mapping and evidence review will inform the sampling for the key informant 319
interviews with stakeholders described later. 320

2.6.2. Qualitative methods 321

2.6.2.1. Key informant interviews 322

The mapping exercise will identify key stakeholders in each community to be approached 323
for interview. Researchers will use a semi-structured interview guide (see Appendix A1), 324
adapted from the BeSD qualitative tools for COVID-19 vaccination, for KIIs. The latter will 325
be conducted face-to-face at the community level or over virtual platforms; depending on 326
COVID-19 conditions at the time, participant preferences, and other practical considerations. 327
The KIIs will explore a range of themes including: participants’ personal, family and community 328
experiences of COVID-19; the impact of COVID-19 on personal and work life; experience of 329
varying lockdown regulations; experience of adherence to NPIs; understanding of COVID-19 330
vaccines; how COVID-19 has shaped their leadership role in the community; and expectations 331
for the future. All research teams will consist of a mix of local language and English-speaking 332
researchers. With permission of participants, interviews will be audio-recorded and thereafter 333
translated as necessary and transcribed. 334

2.6.2.2. Observation 335

On-site researchers will conduct observations of community life in the case study sites. 336
These observations will be centred around locations where community members meet, such as 337
shopping centres, street trading spaces, and/or taxi ranks. The purpose of the observations will 338
be to better understand local community life as well as to document observation about NPI 339
adherence as well as COVID-19 related media and facilities; such as for hand washing. 340

2.6.2.3. Focus group discussions 341

Two types of FGDs will be conducted. The first type will apply an approach called 342
“expression sessions” [35]. The second type of FDG will rely on a semi-structured FGD guides. 343
Expression sessions will be conducted in Phase 1 of the research activities. The second type of 344
FGD will follow in Phase 2. All FGDs will be conducted face-to-face at the research site and 345
will follow COVID-19 precautions including physical distancing, the wearing of face masks, 346

and a well-ventilated venue. FGDs will be capped at six participants for expression sessions and 347
eight for other FGDs. The tools will be piloted in one community and amendments made 348
thereafter. All FGDs will be audio recorded with the permission of participants. Thereafter 349
recordings will be translated as necessary and transcribed. 350

2.6.2.3.1. Expression session focus group discussions 351

Expression sessions will be facilitated with participants in the community who have been 352
severely affected by COVID-19 through personal ill-health, family loss, and/or economic 353
adversity. An expression session is a newly developed approach to collect verbal, visual, and 354
audio-visual data from participants [36]. This approach is informed by the photovoice 355
methodology where participants are required to take photos in response to research questions 356
[37]. The approach encourages active participation in research, and meaningful reflection 357
and engagement with research questions, which is important in the context of COVID-19 358
and vaccine hesitancy. Expression sessions encourage participants to respond to probes by 359
sharing ‘something’ rather than photos only. ‘Something’ could be images, photos, videos 360
(self-taken, downloaded online, or from a book or magazine), a song (audio or lyrics), a drawing 361
(self-drawn or a picture of a drawing), or a poem (self-written or not). Participants will be 362
encouraged to bring their ‘somethings’ to a FGD. Participants will receive a brief formative 363
training session on the methodology along with a set of two research probes to which they can 364
respond by bringing ‘something’ (see Appendix A2). Following the formative session, 365
participants will have one week to gather their ‘somethings’. Expression session FGDs will be 366
facilitated by two researchers and will be conducted in the dominant or preferred language of 367
the group. Each team will include a researcher with local language capacity. Participant 368
information sheets and consent forms will be translated into the local language. 369

2.6.2.3.2. Focus group discussions with semi-structured guides 370

Conventional FGDs will be conducted with three stakeholder groups who are able to 371
address vaccine hesitancy in the community and provide support to the local response to 372
improve acceptance and uptake of vaccines. These FGDs will focus on how to strengthen the 373
community response to vaccine hesitancy and to promote on-going COVID health seeking 374
behaviours. A semi-structured FGD protocol is found in Appendix A3. FGDs will be facilitated 375
by two researchers. It is anticipated that most of these FGDs can be conducted in English but 376
researchers with local language capacity will be included in each research team. Participant 377
information sheets and consent forms will be translated into the local language. 378

2.6.3. Quantitative methods 379

For the quantitative component of the study, we adapted the BeSD quantitative COVID- 380
19 vaccination tool for adults [14]. The tool consists of a questionnaire that assesses four 381
domains i.e., what adults think and feel about COVID-19 vaccines; social processes that drive 382
or inhibit COVID-19 vaccination; individual motivations (or hesitancy) to seek COVID-19 383
vaccination; and practical factors that shape the experience of seeking and receiving COVID- 384
19 vaccination [14]. The BeSD quantitative tool adapted for this study is provided in Appendix 385
A4. The survey will be conducted in English, Afrikaans, and isiZulu since these are 386
predominant languages spoken in the selected communities. Participant information sheets and 387
consent forms will also be translated into the local language. The survey tool will be piloted 388
among 100 adults in one of the first community sites. Where needed additions will be made to 389
the survey to assist with the translation of specific terms. Data will be captured onto tablets 390
during face-to-face interviews conducted by well-trained researchers working in each 391
community site. The researchers will wear masks, practice physical distancing when 392
approaching potential participants, use hand sanitisers regularly, and adhere to all other 393
COVID-19 protocols. Should the period for interviews in any given community coincide with 394
the period of lockdown, face-to-face interviews will be replaced with online questionnaires. 395

2.6.4. COVID-19 precautions 396

The research team will adopt an approach to data collection that is compliant with all the 397
rules pertaining to the COVID-19 response. It is expected that some qualitative data collection 398
will be virtual and meetings to discuss findings with local stakeholders may be virtual where 399
appropriate. Onsite researchers will use personal protective equipment (including face masks 400
and hand sanitisers) and will provide PPE to FGD participants. Meetings and FGDs will be 401
made in well ventilated venues and seating will be appropriately physically distanced. 402

2.7. Data analyses 403

Iterative analyses of all data will occur at each community site as the research team moves 404
from Phase 1 to Phase 3. Data will be triangulated across methods to promote validity. Case- 405
specific and cross-case syntheses will be undertaken as appropriate and as determined by the 406
findings. 407

2.7.1. Qualitative data analyses 408

Qualitative data will be audio recorded, transcribed, and translated where required. 409
Transcripts will be organised and stored using qualitative data software such as MaxQDA and 410
ATLAS.ti (version 9) to facilitate coding and analyses of data. Qualitative data will be subject 411
to thematic analysis [38]. A code book will be developed for the data including both inductive 412
and deductive codes [39], but emphasis will be placed on allowing the data to determine codes 413
[40]. The codes will be discussed between the four qualitative researchers involved in the case 414
studies and with the four study principal investigators. An inter-coder agreement will be 415
established with a portion of the data to verify and enhance data credibility. 416

2.7.2. Quantitative data analyses 417

Quantitative data will be cleaned and stored in the Statistical Package for Social Sciences 418
software, version 27.0 (IBM SPSS Inc, Chicago, IL). Thereafter both the SPSS version 27.0 419

and R/Rstudio v3 softwares will be used for data analyses. The survey data will be summarised 420
as counts and percentages for categorical variables and means with their standard deviations for 421
continuous variables. Analysis of the variance (ANOVA), chi-square tests, and equivalents will 422
be used as appropriate for group comparisons. Logistic regression models will also be used to 423
evaluate the association between selected characteristics and vaccine hesitancy as well as 424
adherence to NPIs. A basic model will be adjusted for age and sex. Expanded multivariable 425
models for the outcome “vaccine hesitancy” will be further adjusted for significant predictors 426
in basic models. Additional data analyses will include subgroup analyses conducted using 427
variables such as race, sex, socio-economic status, geographical location, education levels, and 428
occupation to match areas specific needs. A P-value less than 0.05 will be used to indicate 429
statistically significant results. 430

2.8. Ethics 431

This study proposal was approved by the Human Research Ethics Committees of the 432
University of the Witwatersrand in Johannesburg, South Africa (reference: H21/02/05) on 25 433
March 2021; the Human Sciences Research Council of South Africa (reference: REC 12/04/21) 434
on 20 April 2021; and the South African Medical Research Council (reference: EC022-5/2021) 435
on 27 May 2021. 436

Every effort will be made to ensure that the research process is socially sensitive and 437
respects the rights of all participants. Information sheets will be provided to all potential 438
participants (as hard or electronic copies as the case may be) as well as verbal briefing on the 439
nature and purpose of the interviews or FGDs, emphasising the right of individuals to refuse 440
or withdraw from the interview or FGD at any point. A consent form for participation and for 441
audio-recording will be provided. All participation is voluntary. Participants at face-to-face 442
FGDs will be provided with refreshments. 443

Personal identifiers during KIIs and FGDs will not be used in the reporting and all data 444
will be reported in a summarised form (sex, age) without attributing comments or information 445
to individuals. FGD participants will be informed that while all steps will be taken towards 446
maintaining confidentiality and anonymity, this cannot be guaranteed due to the nature of 447
sharing encouraged by FGDs. While FGD participants will know each other's identity and the 448
information shared, an environment of private sharing will be encouraged; highlighting the 449
importance of maintaining confidentiality for all participants. Furthermore, a local social 450
worker will be available at each site to support or refer any participant that experiences any 451
psychosocial concerns during or after the expression session FGDs. All data will only be used 452
for research purposes and kept with utmost confidentiality, and they will not be accessed by 453
anyone else but the research team. 454

Respondents will be reimbursed for their participation in the study. This is ethically sound 455
and is aligned to the “time, inconvenience, and expenses” (TIE) model [41] and is endorsed by 456
the National Health Research Ethics Council of South Africa [42]. The reimbursement amounts 457
proposed for the study are aligned to TIE that reimburses participants for their time at a rate on 458
par with unskilled labour rates, for their inconvenience and for any expenses (e.g., transport, 459
childcare). The reimbursement for KIIs and FGDs is 150 South African Rands (ZAR) and for 460
the survey is ZAR 100. 461

2.9. Study team 462

The study team is multidisciplinary, consisting of specialists in public health, 463
epidemiology, social science, vaccinology, psychology, political science, project management, 464
and health promotion. The team is led by four principal investigators from the three South 465
African institutions, namely, the Human Sciences Research Council (H.v.R), the Sarraounia 466
Public Health Trust (N.C. and N.P.), and the South African Medical Research Council 467
(C.S.W.). 468

3. Discussion

469

Previous studies have shown high levels of vaccine hesitancy in South Africa [9, 13, 43].
These high levels of are most likely to be driven by multiple factors including personal, interpersonal, community, and social. We therefore propose in this study to determine and co-create with community stakeholders a comprehensive understanding of vaccine hesitancy and opportunities to support the promotion of COVID-19 health seeking behaviours in South Africa. The conceptual framework for the study is based on the socio-ecological model of behaviour change [29] and the BeSD framework for COVID-19 vaccination [14].

Existing vaccine hesitancy measurement tools were mostly designed for use in and validated in high-income countries [10, 15]. Given that vaccine hesitancy is context specific, there is a need to adapt and validate existing COVID-19 vaccine hesitancy tools for use at national and community levels in South Africa. The BeSD tools, which were recently developed under the auspices of WHO, measure both behavioural and social drivers of vaccination. At the time this study was conceived in early 2021, the BeSD model of vaccine hesitancy had not been validated in an African setting. The proposed study will therefore provide insights into the applicability of a novel vaccine hesitancy model in Africa.

The backdrop to the proposed community-based case studies is that the benefits of models of behaviour change that are focused purely on knowledge deficit are limited. Understanding both the behavioural (individual) and social drivers of vaccine hesitancy is critical to increasing COVID-19 vaccine uptake in South Africa. The study applies the socio-ecological model to the investigation of vaccine hesitancy. This model considers the complex interplay between individual, relationship (interpersonal), community, and social factors. It allows us to explore the range of factors that render people conflicted about or opposed to COVID-19 vaccination. Although all levels of the socio-ecological model are relevant for communities, researchers and practitioners in health promotion are often poor at articulating the integration of these levels

and how this determines effective health promotion strategies. One of the most effective 494
applications of the socio-ecological model is at the community level. This is because the 495
enablers or barriers to behaviour change in the four levels (i.e., personal, interpersonal, 496
community, social) of the model can be readily identified. For example, if a local faith leader is 497
speaking out against vaccination, it will most likely have an impact on the social norms of the 498
local community. Similarly, if the local clinic has a reputation for providing poor services, then 499
this too will affect vaccine uptake because it is a barrier to establishing an enabling environment. 500
A bottom-up approach to understanding vaccine hesitancy provides the best opportunity to 501
understand those factors that encourage or impede vaccine uptake. This is enhanced when 502
community stakeholders are actively engaged in providing an interpretation of the intersection 503
of the range of factors at the community level. 504

This mixed methods study is designed as an action research study that is responsive to the 505
local context and is conducted to influence the ongoing management and mitigation of COVID- 506
19 in South Africa. To address the issue of COVID-19 vaccine uptake, an integrated analysis 507
is necessary to provide community stakeholders with a comprehensive understanding of the 508
factors that will assist the identification of helpful health promotion activities at the local level 509
to support COVID-19 vaccine rollout. Convenience sampling is best suited for this type of 510
study, although this would limit the generalisability of the findings to all communities in South 511
Africa. However, we believe that the study will make a substantial contribution to knowledge 512
on COVID-19 response in South Africa, as the case study research will be conducted in four 513
commonplace settings in the country. 514

4. Conclusions

 515

The COVID-19 pandemic continues to have significant health, human, social, and 516
economic impacts on South African society. COVID-19 vaccines and non-pharmaceutical 517
interventions (NPIs) currently offer the most promising means to manage the pandemic. 518

However, their success depends on high levels of uptake and adherence. The aim of this study 519
is to determine and co-create with local stakeholders a comprehensive understanding of vaccine 520
hesitancy and opportunities to support the promotion of other COVID-19 health-promoting 521
behaviours. The study will utilise a mixed-methods, multiple case study design, informed by 522
the socio-ecological model of behaviour change. The study will provide ground-up, locally 523
responsive, and timeous evidence on the factors influencing COVID-19 vaccine acceptance 524
and other health-seeking behaviours to inform the management and mitigation of the pandemic 525
in South Africa. It will also provide insights into the applicability of various global vaccine 526
hesitancy models and research tools to a middle-income country in Africa. 527

Author Contributions: Conceptualization, C.S.W., N.C., N.P., H.v.R; methodology, 528
C.S.W., N.C., N.P., S.C., C.G., PDK, Z.E., S.P., H.v.R; writing—original draft preparation, 529
C.S.W., N.C., N.P., H.v.R.; writing—review and editing, S.C., C.G., Z.E., S.P., G.H., J.S., 530
A.J. and PDK; project administration, N.C., N.P., C.G., Z.E., G.H., J.S; and funding 531
acquisition, H.v.R. All authors have read and agreed to the published version of the 532
manuscript. 533

Informed Consent Statement: Each participant will provide written or digital informed 534
consent. 535


Acknowledgments: This study is conducted by The VaxScenes Study Team which includes 536
Heidi van Rooyen (Human Sciences Research Council (HSRC)), Charles Shey Wiysonge 537
(South African Medical Research Council (SAMRC)) Nancy Coulson (Sarraounia Public 538
Health Trust), Nirvana Pillay (Sarraounia Public Health Trust), Saahier Parker (HSRC), 539
Gregory Houston (HSRC), Marilyn Couch (HSRC), Candice Groenewald (HSRC), Zaynab 540
Essack (HSRC), Londiwe Deborah Shandu (HSRC), Nonkululeko Khuzwayo (HSRC), 541
Nobukhosi Ncube (Sarraounia Public Health Trust), Jane Simmonds (SAMRC), Sara Cooper 542

(SAMRC), Anelisa Jaca (SAMRC), Phelele Bhengu (University of Cape Town), Edison 543
Mavundza (SAMRC), Patrick Katoto (SAMRC). 544

References


1. Abdool Karim, S.S., *The South African Response to the Pandemic*. N Engl J Med, 2020. **382**(24): p. e95. 545
2. Wiysonge, C.S., *South Africa's War on COVID-19. Think Global Health. 20 April 2020. <https://www.thinkglobalhealth.org/article/south-africas-war-covid-19> (accessed 22 December 2021)*. 2020. 547
3. NDOH-a. *National Department of Health, South Africa. Regulations and Relief*. 2021 [cited 2022 14 January 2022]; Available from: <https://sacoronavirus.co.za/guidelines-and-relief/>. 548 549 550
4. NDOH-b. *National Department of Health, South Africa. Covid-19 Daily Updates & Cases*. 2021 [cited 2022 14 January 2022]; Available from: <https://sacoronavirus.co.za/covid-19-daily-cases/>. 551 552
5. Abdool Karim, S.S. and T. de Oliveira, *New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications*. N Engl J Med, 2021. **384**(19): p. 1866-1868. 553 554
6. Boutron, I., et al., *The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic*. Ann Intern Med, 2020. **173**(12): p. 1015-1017. 555 556
7. Ndwandwe, D. and C.S. Wiysonge, *COVID-19 vaccines*. Curr Opin Immunol, 2021. **71**: p. 111-116. 557
8. Sisonke. *Sisonke study: a pragmatic real world phase 3b clinical trial of the single-dose COVID-19 vaccine candidate among frontline healthcare workers in South Africa. <http://sisonkestudy.samrc.ac.za/> (accessed 19 September 2021)*. 2021. 558 559 560
9. NDOH-c. *National Department of Health, South Africa. Vaccine updates*. 2021 [cited 2022 14 January 2022]; Available from: <https://sacoronavirus.co.za/vaccine-updates/>. 561 562
10. Wiysonge, C.S., et al., *Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future?* Hum Vaccin Immunother, 2021: p. 1-3. 563 564
11. Shapiro, G.K., et al., *A critical review of measures of childhood vaccine confidence*. Curr Opin Immunol, 2021. **71**: p. 34-45. 565 566
12. NDOH-d. *National Department of Health, South Africa. COVID-19 vaccine hesitancy in South Africa: Summary of existing studies*. 2021 [cited 2022 14 January 2022]; Available from: <https://sacoronavirus.co.za/2021/04/12/covid-19-vaccine-hesitancy-in-south-africa-summary-of-existing-studies/>. 567 568 569 570
13. Cooper, S., H. van Rooyen, and C.S. Wiysonge, *COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?* Expert Rev Vaccines, 2021. **20**(8): p. 921-933. 571 572
14. WHO, *World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. Interim guidance. 1 April 2021. <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-planning-2021.1> (accessed 22 December 2021)*. 2021. 573 574 575
15. Cooper, S., et al., *Vaccine hesitancy - a potential threat to the achievements of vaccination programmes in Africa*. Hum Vaccin Immunother, 2018. **14**(10): p. 2355-2357. 576 577
16. Machingaidze, S. and C.S. Wiysonge, *Understanding COVID-19 vaccine hesitancy*. Nat Med, 2021. **27**(8): p. 1338-1339. 578 579
17. Machingaidze, S., C.S. Wiysonge, and G.D. Hussey, *Strengthening the expanded programme on immunization in Africa: looking beyond 2015*. PLoS Med, 2013. **10**(3): p. e1001405. 580 581
18. Cooper, S., et al., *Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis*. Cochrane Database Syst Rev, 2021. **10**(10): p. Cd013265. 582 583 584
19. Wilson, S.L. and C. Wiysonge, *Social media and vaccine hesitancy*. BMJ Glob Health, 2020. **5**(10). 585
20. Wiyeh, A.B., et al., *Social media and HPV vaccination: Unsolicited public comments on a Facebook post by the Western Cape Department of Health provide insights into determinants of vaccine hesitancy in South Africa*. Vaccine, 2019. **37**(43): p. 6317-6323. 586 587 588
21. Wiysonge, C.S., *Vaccine hesitancy in South Africa: why we need to adapt validated measures. <https://www.fondation-merieux.org/wp-content/uploads/2017/11/vaccine-acceptance-2018-charles-wiysonge.pdf> (accessed 22 December 2021)*. 2018. 589 590 591
22. Ngcobo, N.J., et al., *Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda*. S Afr Med J, 2018. **109**(1): p. 13-15. 592 593
23. Oduwole, E.O., et al., *Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa*. Vaccine, 2021. **39**(39): p. 5506-5512. 594 595
24. Burnett, R.J., et al., *A profile of anti-vaccination lobbying on the South African internet, 2011-2013*. S Afr Med J, 2015. **105**(11): p. 922-6. 596 597

25. Milondzo, T., et al., *Misinformation Drives Low Human Papillomavirus Vaccination Coverage in South African Girls Attending Private Schools*. *Front Public Health*, 2021. **9**: p. 598625. 598 599
26. Wiysonge, C.S., et al., *Advances in childhood immunisation in South Africa: where to now? Programme managers' views and evidence from systematic reviews*. *BMC Public Health*, 2012. **12**: p. 578. 600 601
27. Larson, H.J., et al., *Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012*. *Vaccine*, 2014. **32**(19): p. 2150-9. 602 603
28. WHO, *Data for action: Achieving high uptake of COVID-19 vaccines – A guidebook for immunization programmes and implementing partners. Draft version of 26 November 2020 (Corsspondence to Ms Lisa Menning: menningl@who.int)* 2020. 604 605 606
29. Bronfenbrenner, U., *Ecological models of human development*, in *International Encyclopedia of Education*. 1994, Elsevier: Oxford. p. 1643-1647. 607 608
30. Swann, C., *Action Research and the Practice of Design*. *Design Issues*, 2002. **18**(1): p. 49-61. 609
31. Grimmer, K., et al., *A South African experience in applying the Adopt-Contextualise-Adapt framework to stroke rehabilitation clinical practice guidelines*. *Health Res Policy Syst*, 2019. **17**(1): p. 56. 610 611
32. Yin, R.K., *Case study research: design and methods*. 5th ed. 2014, Thousand Oaks, CA: Sage Publications, Inc. 612 613
33. NDOH-e. *National Department of Health, South Africa. Update on Covid-19 (29th January 2021)*. 2021 [cited 2021 29 January 2021]; Available from: <https://sacoronavirus.co.za/2021/01/29/update-on-covid-19-29th-january-2021/>. 614 615 616
34. Faul, F., et al., *Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences*. *Behavior Research Methods*, 2007. **39**: p. 175-191. 617 618
35. Groenewald, C., et al., *A qualitative report on learners' experiences and perceptions of the 'It starts today' intervention*. *AwARE.org* 2018. 619 620
36. Groenewald, C. and Z. Essack, *Bring a picture, song or poem: the expression session approach. Paper presented at the 32nd International Congress of Psychology (ICP), Prague, Czech Republic (virtual attendance), 18-23 July 2021*, in *32nd International Congress of Psychology (ICP)*. 2021: Prague, Czech Republic. 621 622 623 624
37. Peabody, C.G., *Using Photovoice as a Tool to Engage Social Work Students in Social Justice*. *Journal of Teaching in Social Work*, 2013. **33**(3): p. 251-265. 625 626
38. Braun, V. and V. Clarke, *Using thematic analysis in psychology*. *Qualitative Research in Psychology*, 2006. **3**(2): p. 77-101. 627 628
39. Bazeley, P. and K. Jackson, *Qualitative Data Analysis with NVivo*. 2nd ed. 2013, London, UK: SAGE Publications Ltd. 629 630
40. Charmaz, K., *Constructing Grounded Theory: A Practical Guide through Qualitative Analysis*. 2nd ed. 2006, London, UK: SAGE Publications Ltd. 631 632
41. Koen, J., et al., *Payment of trial participants can be ethically sound: moving past a flat rate*. *S Afr Med J*, 2008. **98**(12): p. 926-9. 633 634
42. NHREC, *Payment of trial participants in South Africa: Ethical considerations for Research Ethics Committees*. *National Health Research Ethics Council, South Africa*. 2012. 635 636
43. Wiysonge, C.S., et al., *COVID-19 vaccine acceptance and hesitancy among healthcare workers in South Africa*. *Expert Rev Vaccines*, 2022: p. 1-11. 637 638 639



medRxiv preprint doi: <https://doi.org/10.1101/2022.02.21.22271272>; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1



medRxiv preprint doi: <https://doi.org/10.1101/2022.02.21.22271272>; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 2